Gunnar Henrik Heine/X
Jun 23, 2025, 13:27
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:
“RivaGate in DC at ISTH 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”
More posts from ISTH 2025 on Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies